Fig. 4: Species-level differential abundance under dolutegravir versus darunavir/ritonavir and host immune correlations. | Nature Communications

Fig. 4: Species-level differential abundance under dolutegravir versus darunavir/ritonavir and host immune correlations.

From: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial

Fig. 4: Species-level differential abundance under dolutegravir versus darunavir/ritonavir and host immune correlations.

A Species-level differential abundance between dolutegravir and darunavir/ritonavir arms across study time points (0, 24, 48, and 96 weeks), estimated with ANCOMBC2 (abundance ~ treatment * time_point + covariates + (1 | participant_id)). Points represent estimated log₂ fold changes (dolutegravir − darunavir/ritonavir) and error bars denote 95% confidence intervals. Genera with q value < 0.05 and confidence intervals excluding zero are highlighted; the accompanying heatmap shows per-time-point log₂ fold changes and taxon prevalence. Statistics are based on n = 88 independent biological replicates (participants: n = 46 DTG, n = 42 DRV/r) and N = 257 longitudinal observations. B Repeated-measures correlations (rmcorr) between CLR-transformed species abundances and host clinical/immunologic markers (CD4, CD8, activated T cell subsets, CRP, IL-6, TNF-α, sCD14, BMI), shown separately for darunavir/ritonavir and dolutegravir. Colors indicate correlation direction and magnitude; black outlines denote significant associations (q value < 0.05). Source data are provided as a Source data file.

Back to article page